Core Insights - 3D Systems has achieved FDA approval for a 3D bioprinting solution for the regenerative repair of peripheral nerve damage, in collaboration with TISSIUM [1][4] - The newly developed device, COAPTIUM® CONNECT with TISSIUM Light, is a bioabsorbable, atraumatic, and sutureless solution for nerve repair, marking a significant milestone in the industry [1][4] - The global 3D bioprinting market is projected to grow from $1.3 billion in 2024 to $2.4 billion by 2029, indicating strong growth potential for the sector [3] Company Developments - 3D Systems has been a leader in bioprinting for nearly a decade, focusing on developing technologies for regenerative medicine and personalized healthcare [2][3] - The company has collaborated with United Therapeutics Corporation since 2017 to create an unlimited supply of human lungs for transplantation, showcasing its commitment to advancing medical solutions [2][3] - 3D Systems has produced over two million implants and instruments for more than 100 CE-marked and FDA-cleared devices, demonstrating its extensive experience in the medical device sector [3] Industry Impact - The collaboration with TISSIUM sets a new standard for high-resolution elastomeric 3D-printed medical implants, enhancing the capabilities of bioprinting technologies [4] - 3D Systems' innovations in bioprinting are expected to transform patient care by enabling the fabrication of living tissues and developing new therapeutics [5] - The advancements in 3D bioprinting are anticipated to accelerate the adoption of additive manufacturing in the medical field, contributing to improved healthcare delivery [4][5]

Core Insights - CollPlant Biotechnologies has received a patent approval from the European Patent and Trademark Office for its injectable fillers and regenerative breast implant candidates, which are aimed at the aesthetic and reconstructive markets [1][3]. Group 1: Company Developments - The newly allowed patent application covers CollPlant's injectable soft tissue fillers and organ manufacturing technology related to its regenerative breast implant pipeline [2]. - The patent is effective until 2041 and is a key part of the company's strategy to expand its rhCollagen technology into high-value markets [3]. - CollPlant is focusing on building protection around its proprietary technology, enhancing its competitiveness in the aesthetic and reconstructive markets [3]. Group 2: Market Potential - The market for injectable soft-tissue fillers is currently estimated to exceed $6 billion, while the addressable market for breast implants is over $3 billion [3]. - The soft tissue fillers market is projected to grow at a rate of 10%, reaching an estimated $6.3 billion annually [5]. - The regenerative breast implants are designed to regenerate natural breast tissue without triggering an immune response, addressing a significant unmet need in the market [6][7]. Group 3: Product Innovations - CollPlant is developing a photocurable regenerative dermal filler that combines rhCollagen with other substances, intended to provide lifting, sculpturing, and tissue regeneration effects [4]. - The photocurable filler is designed to be injected in a semi-liquid phase and hardens post-injection through light illumination, simplifying the injection process [5].

Core Viewpoint - CollPlant Biotechnologies has announced a definitive agreement for the issuance and sale of 1,200,002 ordinary shares at a price of $3.00 per share, aiming to raise approximately $3.6 million to support its business operations and R&D initiatives [1][2]. Group 1: Offering Details - The offering includes a registered direct offering and a concurrent private placement for the same number of shares at the same price [1][2]. - The warrants issued in the private placement will be exercisable immediately and have a term of three and a half years [1][2]. - The offering is expected to close around June 2, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including collaboration with AbbVie on a dermal filler product candidate, working capital, and funding research and development programs [2]. Group 3: Company Background - CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics [6]. - The company’s products are based on rhCollagen, produced using proprietary plant-based genetic engineering technology [6]. - In 2021, CollPlant entered into a development and commercialization agreement for dermal and soft tissue fillers with Allergan, a subsidiary of AbbVie [7].

Core Insights - CollPlant Biotechnologies reported a significant increase in revenue for Q1 2025, driven by a $2 million milestone payment from AbbVie related to the development of a dermal filler product candidate [1][20] - The company is advancing its regenerative breast implant program, which shows promising preclinical results and aims to provide a safer alternative to traditional breast implants [4][9] - CollPlant is also progressing with its photocurable dermal filler, preparing for clinical studies after completing preclinical testing [10][12] Financial Performance - GAAP revenues for Q1 2025 were $2.1 million, a substantial increase from $98,000 in Q1 2024, primarily due to the AbbVie milestone payment [20] - GAAP gross profit for Q1 2025 was $1.9 million, compared to a gross loss of $447,000 in Q1 2024 [21] - The net loss for Q1 2025 was $1.5 million, or $0.13 per share, an improvement from a net loss of $4.2 million, or $0.37 per share, in Q1 2024 [24] Corporate Developments - CollPlant is focusing on cost optimization and has implemented a workforce reduction plan, resulting in a 20% decrease in staff to ensure financial stability [18] - The company has expanded its international distribution network for its Vergenix™ STR product, which treats tendon injuries, enhancing its market reach [14] - CollPlant received a U.S. patent for its photocurable dermal filler, strengthening its intellectual property portfolio until 2039 [12] Product Development - The regenerative breast implants are designed to regenerate natural breast tissue without immune response, potentially transforming aesthetic and reconstructive procedures [4][9] - The photocurable dermal filler is nearing clinical trials, with capabilities for skin lifting and facial contouring [10][11] - CollPlant's rhCollagen-based BioInk products are positioned as alternatives to animal testing, aligning with FDA initiatives to advance public health [16][17] Balance Sheet and Cash Flow - As of March 31, 2025, CollPlant had cash and cash equivalents of $10.7 million, down from $11.9 million at the end of 2024 [25] - Net cash used in operating activities decreased to $1.2 million in Q1 2025 from $3.3 million in Q1 2024, reflecting improved revenue generation [26] - Total assets as of March 31, 2025, were $17.2 million, a decrease from $18.7 million at the end of 2024 [28]

As filed with the Securities and Exchange Commission on April 12, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Organovo Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Classification Code Number) 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121 (858) 224-1000 Delaware 2836 27-1488943 (I.R.S. Employer I ...